BAYER AG NA
Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?
Read
Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST
BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk
The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.
Read
Commented by Fabian Lorenz on October 9th, 2026 | 07:30 CEST
Deutz Stock Under Pressure! Buy Recommendations for Bayer and Partner MustGrow Biologics
Created and Published on Behalf of MustGrow Biologics Corp.
What is going on with Deutz? The Cologne-based company had emerged as a favourite among investors looking to capitalize on the defence boom. But after more than doubling in just a few months, the stock has recently fallen by around 20%. There are clear reasons for the pullback—but should investors be worried? There is certainly reason for optimism at MustGrow. The US commercialization of the soil-fertility product TerraSante™ has begun, and demand is outpacing supply. Contract manufacturers now need to ramp up production quickly. Analysts expect revenues and earnings to rise sharply in the coming years. A partnership with Bayer is also expected to contribute to this growth. Bayer, meanwhile, plans to expand its US presence with a multibillion-dollar investment. The stock is not currently benefiting from this development. Nevertheless, analysts are recommending the shares as a Buy.
Read
Commented by André Will-Laudien on October 7th, 2026 | 09:00 CEST
Droughts, Floods, Wars! Crisis-Resilient Returns with Global Food Stocks Like Unilever, MustGrow, Bayer and Kraft Heinz
Created and Published on Behalf of MustGrow Biologics Corp.
In times of heightened geopolitical and climate-related crises, the food and agriculture sector is emerging as an increasingly critical industry. Droughts, storms, and devastating floods are presenting the global food industry with ever-greater challenges. Companies in this sector are committed to ensuring basic food security and are also driving the adoption of more sustainable farming practices. For investors, Bayer, Unilever, MustGrow, and Kraft Heinz are being put to the test, with their fundamental strength facing increasingly difficult conditions. British consumer-goods giant Unilever, for example, is placing greater emphasis on regenerative agriculture while leveraging its portfolio of global brands. US food giant Kraft Heinz, meanwhile, is seeking to withstand inflation and volatile supply chains with its portfolio of established consumer brands. At the same time, biotech company MustGrow is positioning itself with sustainable agricultural solutions designed to address increasingly extreme weather conditions, while collaborating with crop-science specialist Bayer. Current challenges are pushing food producers' business models to their limits. A closer look at the key metrics reveals who is truly prepared for the future of food.
Read
Commented by Matthias Schomber on October 6th, 2026 | 07:30 CEST
From Legacy Issues to Growth Opportunities: Why BASF, Bayer and Zefiro Methane Are Worth Watching
Created and Published on Behalf of Zefiro Methane Corp.
BASF is working its way through a cost-cutting program and continues to attract investors with a strong dividend. In addition, the chemical giant plans to acquire its competitor Evonik. This strategic acquisition is intended to significantly expand its market power during challenging times. Whether it succeeds, however, remains to be seen. Bayer, too, is undergoing a painful restructuring to address its legacy issues and reduce debt, but offers bold investors attractive turnaround potential—provided much of this effort succeeds. The dynamics across the Atlantic are quite different. There, Zefiro Methane is turning the remediation of abandoned oil and gas wells in North America into a profitable growth business, with strong sales and a promising chart pattern.
Read
Commented by Armin Schulz on October 3rd, 2026 | 06:00 CEST
Bayer, MustGrow Biologics, BASF: From Yesterday's Crop Protection to Tomorrow's Biologicals
Created and Published on Behalf of MustGrow Biologics Corp.
Major agricultural companies are reshaping their businesses and increasingly looking to small specialists. On September 2, Bayer presented its goals for the agricultural business through 2029 to investors. The Leverkusen-based company aims to generate more than EUR 3 billion in free operating cash flow by then and to assume a leading global role in biologicals through partnerships. That could work in the favor of small developers like MustGrow Biologics. On September 14, BASF commissioned four banks to prepare for a potential initial public offering (IPO) of its agricultural division, which generated EUR 9.6 billion in revenue in 2025. We therefore take a closer look at Bayer, MustGrow Biologics and BASF.
Read
Commented by André Will-Laudien on September 29th, 2026 | 07:10 CEST
Takeovers and Blockbusters on the Horizon! Novo Nordisk, BioNxt and Bayer Keep Taking Center Stage
The storm continues! The biotech sector is facing a massive wave of acquisitions and the approval of new blockbuster drugs. Currently in the spotlight are, above all, the weight-loss sector, innovative drug-delivery platforms, and groundbreaking gene therapies. Major pharmaceutical companies are sitting on bulging cash reserves and are desperately seeking innovative pipelines to offset impending patent expirations. In addition, approval decisions for novel obesity treatments and cancer therapies are driving up valuations across the entire industry. Smaller research firms are making a name for themselves with revolutionary active-ingredient delivery technologies, making them coveted acquisition targets for industry giants. Artificial intelligence in clinical development is also driving major efficiency gains and attracting massive amounts of venture capital. Current market momentum shows industry consolidation is in full swing, and strategic partnerships are setting the pace. Those who stay ahead of the curve in this environment will secure strong revenues for decades to come. For investors and market observers, this realignment offers an exciting starting point with enormous growth opportunities. We dive a little deeper!
Read
Commented by André Will-Laudien on September 21st, 2026 | 07:00 CEST
Gas Prices Above EUR 2.50? Nel ASA, Bayer, MustGrow and K+S in the Spotlight
Created and Published on Behalf of MustGrow Biologics Corp.
The ongoing debate over rising energy costs and the transition toward a greener economy is increasingly reaching gas stations and supermarket shelves. If gasoline prices remain sustainably above EUR 2.50, agricultural producers in particular will come under enormous pressure. Food production remains heavily dependent on fossil fuels, as tractors and harvesters are traditionally powered by agricultural diesel. Higher fuel prices therefore directly increase the cost of producing and transporting our daily food. At the same time, the agricultural sector faces the enormous challenge of reducing its reliance on conventional chemicals and fertilizers and finding more sustainable alternatives. This transformation requires innovative approaches at the intersection of the energy and agricultural sectors. Companies such as Nel ASA are therefore moving into focus, as green hydrogen can play a key role in decarbonizing the agricultural sector and producing cleaner fuels. Specialists such as MustGrow Biologics are also gaining importance by developing biological crop protection products designed to replace chemical alternatives. The traditional fertilizer giant K+S is likewise a key player in the rapidly evolving sector of sustainable food. Where are the opportunities for investors?
Read
Commented by Stefan Bode on September 16th, 2026 | 07:00 CEST
Look Closely, Make Money: Aixtron, ASML, Bayer, Infineon, Nvidia and Zefiro Methane
Created and Published on Behalf of Zefiro Methane Corp.
Amid abrupt share price declines, legacy burdens worth billions and new growth opportunities, the stock market is currently showing just how quickly investor sentiment and market expectations can shift. In these phases, significant opportunities can emerge when short-term nervousness discounts companies with attractive structural prospects. Investors who want to distinguish stock-market noise from real opportunities should look more closely at the background behind the latest headlines. After all, the most compelling opportunities often emerge precisely when the broader market is still reacting turbulently.
Read
Commented by Matthias Schomber on September 10th, 2026 | 09:35 CEST
Is Nel ASA Set to Rebound? Analysts Are Singing Bayer's Praises! RE Royalties Entices with Dividends!
Today we are taking a look at three companies that may all be at a critical turning point. Hydrogen specialist Nel ASA is racing against the clock and must prove its full order book can translate into real profits. On the other hand, there is Bayer—a company that, after years of deep crisis, share prices hovering around EUR 20, and seemingly endless legal battles, has risen like a phoenix from the ashes and is aiming to climb even higher. Last but not least, we take a look at RE Royalties. The project financier is well positioned for the energy transition and is delivering strong returns to shareholders. We examine the numbers, the technical analysis, and the truth behind the latest news.
Read